The DJS Law Group announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Bloomberg reported on January 2, 2025, that Neumora’s experimental depression treatment had “failed” the first of three planned studies. Analysts found the Company’s results “very surprising given the prior data from them and JNJ and reflects a worse-case scenario for the program.” Based on this news, shares of Neumora fell by 81.42% on the same day.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email: David@djslawllp.com

Neumora Therapeutics (NASDAQ:NMRA)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Neumora Therapeutics Charts.
Neumora Therapeutics (NASDAQ:NMRA)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Neumora Therapeutics Charts.